Sigachi Industries Limited announced its audited financial results for the fourth quarter and financial year ended 31 March 2025, alongside a dividend recommendation and a strategic acquisition.

• Financial Highlights (Year Ended 31 March 2025):

  • Standalone Performance:
    • Revenue from operations stood at ₹407.83 crores, up from ₹317.50 crores in the previous fiscal year.
    • Profit for the period increased to ₹47.67 crores from ₹41.01 crores.
    • Basic Earnings Per Share (EPS) was ₹1.41, compared to ₹1.30 in the prior year.
  • Consolidated Performance:
    • Revenue from operations grew to ₹488.24 crores from ₹398.96 crores in the last fiscal year.
    • Profit for the period rose to ₹70.46 crores from ₹57.27 crores.
    • Basic EPS was ₹2.06, up from ₹1.81 previously.

• Quarterly Highlights (Quarter Ended 31 March 2025):

  • Standalone revenue from operations was ₹113.54 crores, a rise from ₹83.66 crores in the same quarter last year. However, standalone profit for the period decreased to ₹6.98 crores from ₹11.73 crores.
  • Consolidated revenue from operations increased to ₹128.20 crores from ₹104.13 crores. Consolidated profit for the period grew to ₹16.17 crores from ₹15.17 crores.

• Dividend Recommendation: The Board of Directors recommended a final dividend of Re. 0.10 per share for the financial year ended 31 March 2025, subject to approval by members at the Annual General Meeting.

• Strategic Acquisition: The company approved the acquisition of an additional 1,07,17,672 equity shares of ₹10 each in Trimax Bio Sciences Private Limited for ₹37.22 crores. This acquisition is through the conversion of advance/loan into equity and is subject to shareholder approvals. Trimax Bio Sciences, a subsidiary engaged in manufacturing pharmaceutical ingredients, bulk drugs, and intermediates, is an USFDA-approved facility. Sigachi Industries' holding in Trimax Bio Sciences will increase from 80% to 84.59% post-acquisition. Trimax Bio Sciences reported a turnover of ₹29 crores for FY 2024-25.

• Auditor Appointments: The Board approved the appointment of M/s. MPR & Associates as Cost Auditors and M/s. PSRV & Co. LLP as Internal Auditors for the financial year 2025-26. M/s. Aakanksha Dubey & Co. was appointed as Secretarial Auditor for five financial years starting from FY 2025-26.

• Audit Opinion: The Statutory Auditors, M/s. Yelamanchi & Associates Chartered Accountants, issued an unmodified/unqualified opinion on both standalone and consolidated audited financial results for the quarter and year ended 31 March 2025.

• Fund Utilization Status:

  • Out of the ₹89.70 crores from the IPO proceeds, ₹61.44 crores remain unutilized, specifically for expansion of MCC capacity at Jhagadia and establishing a CCS project at Dahej.
  • From the Preferential Issue through Convertible Warrants, the company received ₹217.82 crores until 8 February 2025, while ₹68.64 crores were not received from proposed investors. Out of the planned ₹286.45 crores, ₹197.91 crores have been utilized.